526 related articles for article (PubMed ID: 34930261)
1. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.
Cai W; Bao W; Chen S; Yang Y; Li Y
Cancer Cell Int; 2021 Dec; 21(1):698. PubMed ID: 34930261
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
3. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma.
Tan Z; Lei Y; Zhang B; Shi S; Liu J; Yu X; Xu J; Liang C
Front Oncol; 2021; 11():674897. PubMed ID: 34367961
[TBL] [Abstract][Full Text] [Related]
4. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
[TBL] [Abstract][Full Text] [Related]
5. Identification of Transcriptomic Signatures of Pancreatic Ductal Adenocarcinoma-Derived Exosomes That Promote Macrophage M2 Polarization and Predict Prognosis: S100A9 Reveals Tumor Progression.
Tan S; Tang H; Zhang Z; Wang Y; Li H; Shi W; Ye H; Xie P; Zhou J
Clin Med Insights Oncol; 2024; 18():11795549241239042. PubMed ID: 38510315
[TBL] [Abstract][Full Text] [Related]
6. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
[TBL] [Abstract][Full Text] [Related]
7. Identification of solute carrier family genes related to the prognosis and tumor-infiltrating immune cells of pancreatic ductal adenocarcinoma.
Meng Y; Li Y; Fang D; Huang Y
Ann Transl Med; 2022 Jan; 10(2):57. PubMed ID: 35282128
[TBL] [Abstract][Full Text] [Related]
8. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients.
Zhang D; Wang M; Peng L; Yang X; Li K; Yin H; Xia C; Cui F; Huang H; Jin Z
J Oncol; 2021; 2021():4986227. PubMed ID: 34987579
[TBL] [Abstract][Full Text] [Related]
10. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
11. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.
Yang F; He Y; Ge N; Guo J; Yang F; Sun S
Front Immunol; 2023; 14():1203459. PubMed ID: 38268915
[TBL] [Abstract][Full Text] [Related]
12. Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.
Ren M; Feng L; Zong R; Sun H
World J Surg Oncol; 2023 Aug; 21(1):257. PubMed ID: 37605192
[TBL] [Abstract][Full Text] [Related]
13. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Xu QC; Yin XY
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046
[TBL] [Abstract][Full Text] [Related]
14. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
15. The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma.
Lu H; Zheng LY; Wu LY; Chen J; Xu N; Mi SC
Front Oncol; 2022; 12():978921. PubMed ID: 36147906
[TBL] [Abstract][Full Text] [Related]
16. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
17. Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma.
Fang L; Chen S; Gong H; Xia S; Guan S; Quan N; Li Y; Zeng C; Chen Y; Du J; Liu S
Front Oncol; 2022; 12():1060508. PubMed ID: 36727081
[TBL] [Abstract][Full Text] [Related]
18. Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma.
Huang X; Zhao L; Jin Y; Wang Z; Li T; Xu H; Wang Q; Wang L
Front Oncol; 2022; 12():827051. PubMed ID: 35433491
[TBL] [Abstract][Full Text] [Related]
19. Values of a novel pyroptosis-related genetic signature in predicting outcome and immune status of pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Li JH; Xu QC; Yin XY
Gastroenterol Rep (Oxf); 2022; 10():goac051. PubMed ID: 36196256
[TBL] [Abstract][Full Text] [Related]
20. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
Front Immunol; 2021; 12():728062. PubMed ID: 34691034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
